Drug Safety Clinical Trial
Official title:
Pharmacokinetics of Ceftaroline in Normal and Obese Subjects
The purpose of this study is to characterize plasma and urinary concentrations of ceftaroline following intravenous administration of a single dose of ceftaroline 600 mg in healthy subjects who are normal weight, overweight, and obese.
This study is planned to be a Phase I, open-label, single period, single-dose pharmacokinetic study conducted in 32 healthy adult male and female subjects. Adult subjects will be recruited and assigned to one of four groups based on their body mass index and total body weight. Subject will receive a single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion. Serial blood and urine samples will be collected over the next 12 hours to determine serum and urinary pharmacokinetics of ceftaroline. Safety evaluations will be assessed throughout the study and will include physical examination, vital sign monitoring, clinical laboratory tests (serum chemistry and hematology), pregnancy testing (female subjects only), monitoring of adverse events, and recording of concomitant medications. ;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01425502 -
Data-driven Quality Improvement in Primary Care - Trial
|
N/A | |
| Recruiting |
NCT01756183 -
Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer
|
Phase 2 | |
| Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01757860 -
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01179854 -
Remegal Different Doses in Patients With Refractory Partial Seizures
|
Phase 2 | |
| Completed |
NCT00376415 -
A Safety Study of Lessertia Frutescens in Adults.
|
Phase 1 | |
| Active, not recruiting |
NCT01722916 -
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
|
Early Phase 1 | |
| Completed |
NCT01727778 -
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01475097 -
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
|
Phase 4 | |
| Completed |
NCT01412658 -
Clinical Safety of a Novel Milk Protein Peptide
|
Phase 1 | |
| Terminated |
NCT01847222 -
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
|
Phase 1 | |
| Unknown status |
NCT01633099 -
Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients
|
Phase 3 | |
| Recruiting |
NCT01297842 -
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
|
Phase 4 | |
| Completed |
NCT01284582 -
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
|
Phase 1 | |
| Completed |
NCT01556607 -
A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma
|
Phase 1 | |
| Completed |
NCT01557270 -
Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery
|
Phase 3 | |
| Completed |
NCT01319903 -
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
|
Phase 1 | |
| Completed |
NCT01271569 -
A Study to Assess the Efficacy and Safety of Fospropofol Disodium
|
Phase 1 | |
| Recruiting |
NCT04785027 -
Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT01428882 -
Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy
|
Phase 4 |